Targeted Therapy in Melanoma: Recent Progress
CME Course Duration:
Start Date: 12-21-2009
This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who screen for and/or treat melanoma.
Faculty Disclosure Statement
Dr. Keith T. Flaherty has disclosed he serves as a consultant to Genentech, Glaxo SmithKline, and Roche.
Physician/Nurse Accreditation Statement
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Each physician should claim only those credits commensurate with the extent of his or her participation in the activity.
1 contact hour of Continuing Nursing Education will be granted by the University of Pittsburgh Medical Center. The University of Pittsburgh Medical Center is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
We gratefully acknowledge an educational grant from Schering-Plough Corporation in support of this activity.
This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, PharmAdura, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.
Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.